Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8993904 | 1.00 | LPAR3 (0.47) | LPAR3LPAR2PPARDTSHRALDH1A1 | |
| SCHEMBL9701750 | 1.00 | LPAR3 (0.47) | LPAR3LPAR2PPARDTSHRALDH1A1 | |
| SCHEMBL1219734 | 0.98 | PPARD (0.47) | LPAR3LPAR2PPARDTSHRALDH1A1 | |
| SCHEMBL2957697 | 0.92 | PPARD (0.48) | LPAR3LPAR2PPARDTSHRALDH1A1 | |
| SCHEMBL4433689 | 0.84 | LPAR3 (0.51) | LPAR3LPAR2TSHRALDH1A1 | |
| SCHEMBL212199 | 0.84 | PPARD (0.52) | LPAR3LPAR2PPARDTSHRALDH1A1 | |
| SCHEMBL11514496 | 0.83 | PPARD (0.61) | PPARDTSHRTDP1 | |
| SCHEMBL7268183 | 0.83 | PPARD (0.61) | PPARDTSHRTDP1 | |
| SCHEMBL11323349 | 0.83 | PPARD (0.61) | PPARDTSHRTDP1 | |
| SCHEMBL17764807 | 0.82 | PPARD (0.47) | PPARDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254287-A1 | Thiol-ene-based polymerizable composition | KARL LEIBINGER ASSET MANAGEMENT GMBH & CO. KG (DE) | 2024-08-01 | — | — | US | disclosed |
| CN-111183543-B | Ceramic-polymer composite single ion conductive thin film electrolyte | 罗伯特·博世有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-110945084-B | Phosphonate surface functionalized titanium dioxide nanoparticles | 巴斯夫欧洲公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-111183543-A | Ceramic-polymer composite single ion conductive film electrolyte | 罗伯特·博世有限公司 | 2020-05-19 | — | — | CN | disclosed |
| US-9657042-B2 | Silane compounds and use of same for functionalizing solid supports and immobilizing biological molecules on these supports | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2017-05-23 | — | — | US | disclosed |
| US-9657042-B2 | Silane compounds and use of same for functionalizing solid supports and immobilizing biological molecules on these supports | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2017-05-23 | — | — | US | disclosed |
| US-7754200-B2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754200-B2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754200-B2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090208451-A1 | HALOGEN PHOSPHONATE MONOESTERS | INTEGRIGEN, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20030096328-A1 | Serine/threonine hydrolase proteins and screening assays | BURNHAM INSTITUTE | 2003-05-22 | — | — | US | disclosed |
| WO-2003023355-A2 | SERINE/THREONINE HYDROLASE PROTEINS AND SCREENING ASSAYS | THE BURNHAM INSTITUTE (US) | 2003-03-20 | — | — | WO | disclosed |
| EP-1275006-A2 | PROTEOMIC ANALYSIS USING ACTIVITY-BASED PROBE LIBRARIES | The Scripps Research Institute (US) | 2003-01-15 | — | — | EP | disclosed |
| US-20020182652-A1 | Proteomic analysis | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2002-12-05 | — | — | US | disclosed |
| WO-2002063271-A2 | ACTIVITY BASED PROBE ANALYSIS | ACTIVX BIOSCIENCES, INC. (US) | 2002-08-15 | — | — | WO | disclosed |
| US-20020064799-A1 | Proteomic analysis | THE SCRIPPS RESEARCH INSTITUTE OF AN ASSIGNMENT | 2002-05-30 | — | — | US | disclosed |
| US-20020045194-A1 | Proteomic analysis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-04-18 | — | — | US | disclosed |
| US-20020040275-A1 | Proteomic analysis | THE SCRIPPS RESEARCH INSTITUTE | 2002-04-04 | — | — | US | disclosed |
| WO-2001077668-A2 | PROTEOMIC ANALYSIS USING ACTIVE-SITE DIRECTED PROBES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2001-10-18 | — | — | WO | disclosed |
| WO-2001077684-A2 | PROTEOMIC ANALYSIS USING ACTIVITY-BASED PROBE LIBRARIES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090208451-A1 | HALOGEN PHOSPHONATE MONOESTERS | FCGRT, PTMS, DNPEP | LPAR3 1556/4885LPAR2 3253/4885PPARD 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.